Therapeutics and COVID-19: living guideline

Published by Dr. Bram Rochwerg, Dr. Reed Siemieniuk and Dr.Michael Jacobs (GDG co-chairs) on Mar 31, 2021

Disclaimer

© World Health Organization 2021. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

WHO reference number: WHO/2019-nCoV/therapeutics/2021.1

Sponsors

This guideline has been developed by the World Health Organisation (WHO) with methodological support from the MAGIC Evidence Ecosystem Foundation. It has been published as WHO guidance. No specific funding has been provided beyond in-kind resources by the organisations involved, including the BMJ.

Contact

Abstract

Language

en

PICOS

PICO 1.1

Population
Patients with COVID-19 infection (all disease severities)
Intervention
Ivermectin
Comparator
Usual care
Outcomes

PICO 2.1

Population
Patients with COVID-19 infection (all disease severities)
Intervention
Hydroxychloroquine + usual care
Comparator
Usual care
Outcomes

PICO 2.2

Population
Patients with COVID-19 infection (all disease severities)
Intervention
Hydroxychloroquine + azithromycin usual care
Comparator
Usual care
Outcomes

PICO 2.3

Population
Patients with COVID-19 infection (all disease severities)
Intervention
Hydroxychloroquine + usual care
Comparator
Usual care
Outcomes

PICO 3.1

Population
Patients with COVID-19 (all disease severities)
Intervention
Lopinavir-ritonavir
Comparator
Standard care
Outcomes

PICO 4.1

Population
Patients with COVID-19 infection (all disease severities)
Intervention
Remdesivir + usual care
Comparator
Usual care
Outcomes

PICO 4.2

Population
Patients with critical COVID-19 infection
Intervention
Remdesivir + usual care
Comparator
Usual care
Outcomes

PICO 4.3

Population
Patients with severe COVID-19 infection
Intervention
Remdesivir + usual care
Comparator
Usual care
Outcomes

PICO 4.4

Population
Patients with non-severe COVID-19 infection
Intervention
Remdesivir + usual care
Comparator
Usual care
Outcomes

PICO 4.5

Population
Patients with COVID-19 infection (mortality subgroup analysis)
Intervention
Remdesivir + usual care
Comparator
Usual care
Outcomes

PICO 5.1

Population
Patients with critical COVID-19
Intervention
Steroids
Comparator
Standard Care
Outcomes

PICO 5.2

Population
Patients with severe COVID-19
Intervention
Steroids
Comparator
Standard Care
Outcomes

PICO 5.3

Population
Patients with non-severe COVID-19
Intervention
Steroids
Comparator
Standard Care
Outcomes

PICO 5.4

Population
Patients with COVID-19 infection (all disease severities)
Intervention
Steroids
Comparator
Standard Care
Outcomes

PICO 5.5

Population
Patients with critical, severe, non-severe COVID-19 infection [Mortality]
Intervention
Steroids
Comparator
Standard care
Outcomes